Ausgabe 2/2009
Inhalt (12 Artikel)
Effects of rimonabant on progression of atherosclerosis: Increased risks and doubtful benefits
Girardin Jean-Louis, Ferdinand Zizi, Samy I. McFarlane
Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (the JUPITER trial)
Nathan D. Wong
Optimal dietary intake for cardiovascular risk reduction
Wendy M. Miller, Katherine E. Nori Janosz, Kerstyn C. Zalesin, Peter A. McCullough
Obesity, anemia, and cardiovascular risk in patients with chronic kidney disease: Overview and pathophysiologic insights
Andrew C. Miller, Brandon Smaglo, Samy I. McFarlane
Contemporary strategies for weight loss and cardiovascular disease risk factor modification
Alison M. Hill, Penny M. Kris-Etherton
Carotid intima-media thickness and carotid plaques in cardiovascular risk assessment
Samuel A. Daneshvar, Tasneem Z. Naqvi
Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?
Benoit J. Arsenault, Erik S. G. Stroes, S. Matthijs Boekholdt
Short-term versus lifetime risk assessment for cardiovascular disease: Pros, cons, and clinical implications
John T. Wilkins, Donald M. Lloyd-Jones
Calcified versus noncalcified atherosclerosis: Implications for evaluating cardiovascular risk
Khurram Nasir, Juan J. Rivera, Hyuk-Jae Chang, Matthew J. Budoff, Roger S. Blumenthal